证券代码：688198 证券简称：佰仁医疗 公告编号：2023-023 北京佰仁医疗科技股份有限公司 关于自愿披露创新产品"限位可扩张人工生物心脏瓣膜"获批注 册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，经国家药品监督管理局审查，北京佰仁医疗科技股份有限公司（以下简 称"公司"或"佰仁医疗"）自主研发的创新产品限位可扩张人工生物心脏瓣膜（国械 注准20233131137）获准注册，用于替换病变、损伤、畸形的主动脉瓣、二尖瓣和三 尖瓣或替换先前植入的人工主动脉瓣、二尖瓣和三尖瓣，作为首个可覆盖三个瓣 位，具有可扩性外科生物瓣的成功研制，标志着人工生物瓣进入可扩理念的时代， 对即将迎来的介入瓣中瓣治疗具有里程碑意义。现公告如下： 限位可扩张人工生物心脏瓣膜是目前外科牛心包生物瓣的升级迭代产品，通过 对原有瓣座组件的独特设计和工艺实现，赋予了原有外科牛心包生物瓣不仅可单向 扩张且实现了限位可扩，以保证了产品升级后的安全和有效。 半个多世纪以来，外科牛心包生物瓣的研究主要聚焦在瓣叶组织的抗钙化和瓣 叶交界以及瓣 ...

Financial Performance - The net assets attributable to shareholders of the listed company increased to ¥1,101,501,079.28, representing an 11.32% increase compared to the previous year[14]. - Total assets reached ¥1,179,660,158.66, reflecting a 14.42% growth year-over-year[14]. - In Q1 2022, operating revenue was ¥66,005,581.98, with net profit attributable to shareholders at ¥13,606,919.59[16]. - Q2 2022 saw operating revenue rise to ¥74,929,847.51, with net profit attributable to shareholders increasing to ¥23,691,771.32[16]. - The third quarter reported operating revenue of ¥79,804,664.33 and net profit attributable to shareholders of ¥22,554,571.71[16]. - In Q4 2022, operating revenue was ¥74,426,625.90, with net profit attributable to shareholders reaching ¥35,285,243.09[16]. - The total comprehensive income for the year amounted to ¥51,258,095.07, with a significant portion attributed to the increase in retained earnings[7]. - The company achieved a net profit of 145.43 million yuan, representing a year-on-year growth of 24.67% after excluding the impact of share-based payment expenses[51]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 25% year-over-year growth[101]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 20% to 1.8 billion RMB[101]. Cash Flow and Expenses - The company reported a net cash flow from operating activities of ¥23,085,270.23 in Q1 2022, increasing to ¥42,907,029.96 in Q2 2022[16]. - The net cash flow from operating activities increased by 68.44% to ¥128,847,319.36, primarily due to growth in sales revenue[164]. - The net cash flow from investing activities was affected by the purchase of large bank deposits and the recovery of previous bank investment funds[154]. - Management expenses increased by 25.46% due to rising consulting service fees and personnel compensation, excluding share-based payment impacts[154]. - R&D expenses decreased by 6.37% to ¥55,147,643.80, with a 6.11% decrease when excluding share-based payment factors[163]. Product Development and Innovation - The company is focusing on the development of innovative products to meet the unmet clinical needs of patients, with only 10% of moderate to severe patients receiving surgical or percutaneous valve interventions[30]. - The company has strengthened its core technology in animal tissue engineering and chemical modification processes, ensuring steady improvement in product quality and innovation capabilities[39]. - The company is actively expanding its product offerings, including a new pulmonary artery conduit designed for complex congenital heart surgery, which has received patent authorization in major global regions[46]. - The company is committed to enhancing research and development investments, focusing on basic research to support product innovation[53]. - The company has established a professional team for molecular biology and biochemistry to improve product development and testing processes[39]. - The company is focusing on product innovation in the field of animal-derived materials, aiming to lead R&D in this area[173]. - The company is accelerating the clinical enrollment of interventional valve products, with positive clinical results supporting product registration[174]. - The company plans to enhance its R&D capabilities and maintain innovation advantages by increasing talent acquisition and improving incentive mechanisms[173]. Market Position and Strategy - The company is positioned as a leading player in the domestic market, competing primarily with imported products and focusing on unique offerings[33]. - The market for valve disease is expected to grow significantly due to the aging population and increasing clinical demand for innovative treatments[31]. - The company is positioned to benefit from the increasing demand for comprehensive treatment solutions for patients with multiple valve diseases[61]. - The company is focusing on online market operations and continuing clinical trials for in-development products amid pandemic-related challenges[156]. - The company is strengthening its market promotion capabilities and enhancing its sales network to improve brand image and direct sales capabilities[195]. Corporate Governance and Compliance - The company emphasizes the importance of independent governance and compliance, ensuring that there are no violations related to insider trading or information leaks[199]. - The company is committed to continuous improvement of its corporate governance structure and internal control mechanisms to support sustainable development[199]. - The company has not reported any significant changes in its governance structure or compliance with regulations[177]. Shareholder Returns - The company plans to distribute a cash dividend of 5.00 RMB per 10 shares, totaling 67,836,294.00 RMB, which represents 71.30% of the net profit attributable to the parent company[125]. - The company’s cash dividend distribution plan has been approved by the board and will be submitted for shareholder approval[125]. Sales and Revenue Growth - Revenue from the East China region reached 81,932,293.85 RMB, with a year-on-year increase of 31.12%[134]. - The gross profit margin for the heart valve replacement and repair segment is 96.50%, maintaining a high level[135]. - The company reported a revenue of 284,944,767.40 RMB from distributor sales, reflecting a year-on-year increase of 15.91%[134]. - The sales revenue from hospital sales reached 10,120,584.83 RMB, with a significant year-on-year increase of 69.81%[134]. - Direct sales to hospitals saw a significant increase, with revenue growing by 69.81% year-on-year[157]. Research and Development - The company has invested in foundational research, establishing multiple laboratories to accelerate product development, including a "Biochemical and Molecular Biology" lab and a "Big Data and Intelligent Research Center"[84]. - The company has accumulated significant clinical evidence for its surgical biological patches, which are now recognized for their effectiveness in preventing lung tissue leakage during surgeries[114]. - The company is focusing on the development of innovative products, including a new TAVR system that aims to reduce complications and simplify the procedure[73]. - The company has filed for two invention patents and four PCT applications related to new heart valve systems, indicating ongoing innovation in product development[115].

Financial Performance - The company's operating revenue for Q1 2023 was ¥64,891,611.97, representing a decrease of 1.69% compared to the same period last year[7]. - Net profit attributable to shareholders for Q1 2023 was ¥11,698,274.57, down 14.03% year-over-year[7]. - The net profit after deducting non-recurring gains and losses was ¥9,016,201.18, a decline of 17.30% compared to the previous year[7]. - The net cash flow from operating activities was ¥19,517,608.89, reflecting a decrease of 15.45% year-over-year[7]. - Total operating revenue for Q1 2023 was CNY 64,891,611.97, a decrease of 1.7% compared to CNY 66,005,581.98 in Q1 2022[31]. - Net profit for Q1 2023 was CNY 11,425,536.20, down 15.8% from CNY 13,570,614.66 in Q1 2022[34]. - The company reported a profit before tax of CNY 14,133,152.54, down 13.1% from CNY 16,264,121.23 in the previous year[34]. - The total comprehensive income for the first quarter of 2023 was CNY 11,461,029.65, a decrease of 16.6% compared to CNY 13,744,523.81 in the same period of 2022[36]. - The company reported a basic and diluted earnings per share of CNY 0.09, down from CNY 0.10 in the same quarter last year[36]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,186,704,092.06, a slight increase of 0.60% from the end of the previous year[10]. - Total current assets as of March 31, 2023, amounted to ¥652,163,383.23, a decrease of 9.94% from ¥724,374,884.28 in the previous year[23]. - Cash and cash equivalents decreased to ¥98,100,152.32 from ¥128,298,513.56, representing a decline of 23.51%[23]. - Trade receivables decreased to ¥50,470,441.14 from ¥57,981,942.38, a reduction of 13.14%[23]. - Total liabilities decreased to CNY 64,265,950.94 from CNY 80,173,470.91 year-over-year, a reduction of 19.8%[30]. - Shareholders' equity increased to CNY 1,124,725,271.02, up from CNY 1,101,501,079.28, representing a growth of 2.1%[30]. - The company’s total assets amounted to CNY 1,186,704,092.06, compared to CNY 1,179,660,158.66 in the previous year, indicating a slight increase[31]. Cash Flow - The net cash flow from operating activities was CNY 19,517,608.89, down 15.5% from CNY 23,085,270.23 in Q1 2022[39]. - Cash inflow from operating activities totaled CNY 77,962,891.01, an increase of 9.5% compared to CNY 71,507,150.55 in the previous year[39]. - The cash outflow from operating activities was CNY 58,445,282.12, which increased by 20.8% from CNY 48,421,880.32 in Q1 2022[39]. - The net cash flow from investing activities was negative at CNY -48,247,368.69, compared to a positive CNY 9,898,930.07 in Q1 2022[41]. - The cash and cash equivalents at the end of the period were CNY 98,617,977.18, a decrease from CNY 185,040,249.87 at the end of Q1 2022[41]. - The cash inflow from investment activities was CNY 296,456,007.58, down from CNY 363,086,414.23 in Q1 2022[40]. - The cash outflow from investment activities totaled CNY 344,703,376.27, a slight decrease from CNY 353,187,484.16 in the same period last year[40]. Research and Development - Research and development expenses totaled ¥17,404,587.43, accounting for 26.82% of operating revenue, an increase of 4.56 percentage points[10]. - R&D expenses rose to CNY 17,404,587.43, reflecting an 18.4% increase from CNY 14,695,524.66 in Q1 2022[31]. Operational Challenges - The company faced operational challenges in January due to the COVID-19 pandemic, impacting nearly half of the sales period[10]. - The company recognized share-based payment expenses of ¥11,972,800, which affected the net profit calculation[10]. Other Information - Non-recurring gains included government subsidies amounting to ¥386,590.80 and other income totaling ¥2,601,667.70[11]. - The company has not disclosed any new product developments or market expansion strategies in the current report[19]. - The company’s financial expenses showed a decrease, with interest expenses at CNY 16,077.44 compared to CNY 20,901.84 in Q1 2022[31]. - Other comprehensive income after tax for Q1 2023 was CNY 35,493.45, down from CNY 173,909.15 in the same quarter last year[34]. - The company paid CNY 24,907,230.46 in employee compensation, an increase of 15.5% from CNY 21,679,355.16 in the previous year[39]. - The company’s short-term borrowings and other liabilities were not detailed in the provided data, indicating a focus on asset management and liquidity[26]. - The top ten shareholders include significant holdings by private equity funds, indicating strong institutional interest in the company[21].

关于召开2022年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京佰仁医疗科技股份有限公司（以下简称"公司"）已于2023年4月20日发布 公司2022年年度报告，为便于广大投资者更全面深入地了解公司2022年度经营成果、 财务状况，公司计划于2023年4月27日上午10:00-11:00举行2022年度业绩说明会， 就投资者关心的问题进行交流。 证券代码：688198 证券简称：佰仁医疗 公告编号：2023-011 北京佰仁医疗科技股份有限公司 四、投资者参加方式 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2022年度的经营成果及财 务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资 者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2023 年 4 月 27 日（星期四）上午 10:00-11:00 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.ss ...

北京佰仁医疗科技股份有限公司 投资者关系活动记录表 证券简称：佰仁医疗 证券代码：688198 编号：2022 年 3-4 月 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

北京佰仁医疗科技股份有限公司 投资者关系活动记录表 证券简称：佰仁医疗 证券代码：688198 编号：2022 年 5 月 | --- | --- | --- | |-----------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥79,804,664.33, representing a year-on-year increase of 35.52%[5] - Net profit attributable to shareholders for Q3 2022 was ¥22,554,571.71, up 60.31% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,503,973.23, reflecting a significant increase of 122.20% year-on-year[5] - The net profit for the first three quarters of 2022, excluding share-based payment effects, was ¥101,134,200, reflecting a year-on-year growth of 15.33%[9] - Net profit for the third quarter of 2022 was ¥59,430,836.75, compared to ¥40,102,904.60 in the same quarter of 2021, reflecting an increase of about 48.1%[38] - The total comprehensive income attributable to the parent company was CNY 59,942,428.47, an increase from CNY 40,441,954.03 in the previous year, representing a growth of approximately 48.2%[41] Earnings Per Share - The basic earnings per share for Q3 2022 was ¥0.17, an increase of 54.55% compared to the same period last year[9] - The basic earnings per share for the current reporting period is 54.55 yuan, reflecting growth due to the increase in net profit[20] - The diluted earnings per share for the current reporting period is also 54.55 yuan, with similar growth reasons as the basic earnings[20] - Basic and diluted earnings per share increased to CNY 0.44 from CNY 0.30, reflecting a growth of 46.7% year-over-year[41] Cash Flow - The company reported a net cash flow from operating activities of ¥94,707,665.75 for the year-to-date, which is a 70.58% increase year-on-year[5] - The net cash flow from operating activities for the year-to-date is 70.58 million, primarily due to increased cash received from sales and reduced tax payments[20] - Cash flow from operating activities generated CNY 94,707,665.75, compared to CNY 55,519,532.49 in the same period last year, indicating an increase of 70.7%[44] - The net cash flow from investment activities was CNY 81,955,175.83, a significant recovery from a negative CNY 47,020,839.96 in the previous year[46] - The company reported a net increase in cash and cash equivalents of CNY 138,914,441.44, contrasting with a decrease of CNY 446,861.94 in the previous year[46] Assets and Liabilities - The total assets as of the end of Q3 2022 reached ¥1,111,157,236.20, a 7.78% increase from the end of the previous year[9] - Total assets as of the end of the reporting period were ¥1,111,157,236.20, compared to ¥1,030,955,850.61 at the end of the previous year, marking an increase of about 7.8%[36] - Total liabilities increased to ¥61,533,760.28 from ¥42,728,523.60, representing a rise of approximately 43.9%[34] - The company's equity attributable to shareholders reached ¥1,051,328,891.42, an increase from ¥989,510,316.64, reflecting a growth of about 6.2%[36] Research and Development - Research and development expenses totaled ¥16,672,860.59 for the quarter, accounting for 20.89% of operating revenue, a decrease of 4.68 percentage points year-on-year[9] - Research and development expenses for the third quarter of 2022 amounted to ¥44,599,372.43, up from ¥37,493,961.95 in the previous year, indicating a growth of approximately 19.3%[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 3,003, with the largest shareholder holding 61.89% of the shares[21] - The largest shareholder, Jin Lei, holds 83,972,092 shares, representing 61.89% of the total shares[21] Market Strategy - The company is focused on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided content[20] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[41] Financial Position - The company has a significant cash position with monetary funds amounting to 295.69 million as of September 30, 2022, compared to 156.78 million in the previous year[28] - The trading financial assets are reported at 462.48 million, down from 615.53 million in the previous year[28] - The company's cash and cash equivalents were not explicitly detailed, but total current assets were reported at ¥869,507,378.04, slightly up from ¥853,189,726.22[36] - The company reported a decrease in financial expenses, with a net financial cost of -¥626,067.14 compared to -¥1,198,469.76 in the previous year[36] - The company’s inventory increased to ¥26,166,137.94 from ¥21,962,429.92, indicating a rise of approximately 19.9%[36] - The company’s total operating costs for the first three quarters were ¥162,476,410.31, compared to ¥154,154,255.17 in the same period of 2021, reflecting an increase of about 5.5%[36] Tax and Financing Activities - The company received CNY 6,275,189.06 in tax refunds, a substantial increase from CNY 277,860.14 in the previous year[44] - The total cash outflow from financing activities was CNY 49,089,050.11, compared to CNY 19,727,931.27 in the previous year, indicating a rise of 148.5%[46]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with a total revenue of 500 million RMB, representing a 25% year-over-year growth[2]. - The company reported a revenue of RMB 100 million for the first half of 2022, reflecting a year-on-year growth of 15%[20]. - The company expects a revenue guidance of RMB 220 million for the full year 2022, indicating a projected growth of 10%[20]. - The company achieved operating revenue of CNY 140,935,429.49, representing a year-on-year increase of 13.13%[28]. - The net profit attributable to shareholders reached CNY 37,298,690.91, up 41.51% compared to the same period last year[28]. - The company reported a total revenue of 15,376 million RMB for the first half of 2022, with a net profit of 2,792.65 million RMB, reflecting a significant increase compared to the previous year[105]. User Growth and Market Expansion - User data showed an increase in active users, reaching 1.2 million, which is a 15% increase compared to the previous period[2]. - The user base increased to 500,000 active users, representing a 20% increase compared to the previous period[20]. - The company is expanding its market presence in Southeast Asia, with plans to establish two new distribution centers by the end of 2022[2]. - Market expansion efforts include entering three new provinces in China, aiming to increase market share by 25% in these regions[20]. Product Development and Innovation - New product development includes the launch of a next-generation heart valve, expected to enter the market by Q4 2022, which is anticipated to capture 10% of the market share within the first year[2]. - The company is focusing on the development of new artificial heart valve technologies, with an investment of RMB 30 million allocated for R&D in 2022[20]. - The company has launched a new line of bioengineered materials, which is expected to contribute an additional RMB 10 million in revenue by Q4 2022[20]. - The company is actively developing new products, including a new type of tricuspid/mitral valve ring currently under registration review[45]. - The company is developing a limit-expandable artificial biological heart valve, targeting the increasing demand for biological valves in mitral and tricuspid positions[74]. Research and Development - The company has invested 50 million RMB in R&D for innovative medical devices, focusing on minimally invasive technologies[2]. - The company’s R&D expenditure accounted for 19.82% of operating revenue, an increase of 1.81 percentage points compared to the previous year[28]. - The total R&D investment for the period was approximately ¥27.93 million, a 24.46% increase from the previous year, representing 19.82% of operating revenue[93]. - The R&D team has expanded to 57 personnel, representing 17.87% of the total workforce, with an average salary of 99,940.76 RMB, up from 85,497.45 RMB in the previous year[106]. Financial Health and Risks - The company has identified potential risks related to supply chain disruptions, which could impact production timelines[2]. - The company faces risks related to new product development and market acceptance, which may impact future sales performance[125]. - The ongoing COVID-19 pandemic continues to pose macroeconomic risks, affecting short-term operational performance[130]. - The company reported a significant increase in accounts payable, which rose by 92.39% to CNY 29,441,359.70, indicating potential growth in operational scale[136]. Compliance and Governance - The management emphasized the importance of maintaining compliance with regulatory standards to mitigate operational risks[2]. - The company confirmed that all related party transactions during the reporting period were disclosed accurately and completely, with no significant omissions[176]. - The company will comply with the issuer's articles of association and related transaction management systems to avoid conflicts of interest[176]. - The company has committed to strict supervision of fundraising projects to ensure the proper and legal use of raised funds[192]. Strategic Acquisitions - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's product portfolio and increase market share by 5%[2]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, targeting at least two potential companies by the end of 2022[20]. Environmental and Social Responsibility - The company reported a COD emission concentration of 20 mg/L, significantly below the standard of 500 mg/L[156]. - The company has committed to energy-saving measures and the application of new technologies in new projects to enhance energy utilization[161]. - The company has established a hazardous waste management plan and emergency response plan, which have been approved by the relevant authorities[160].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 15%[22]. - The net profit for the year was RMB 300 million, which is an increase of 20% compared to the previous year[22]. - The company's operating revenue for 2021 was CNY 251.82 million, a year-on-year increase of 38.42% compared to CNY 181.92 million in 2020[30]. - The net profit attributable to shareholders of the listed company for 2021 was CNY 51.20 million, a decrease of 9.42% from CNY 56.53 million in 2020[30]. - The net profit after deducting non-recurring gains and losses was CNY 35.71 million, down 12.98% from CNY 41.04 million in 2020[30]. - The net cash flow from operating activities increased by 50.69% to CNY 76.49 million from CNY 50.76 million in 2020[30]. - The company's total assets at the end of 2021 were CNY 1,030.96 million, an increase of 18.31% from CNY 871.44 million at the end of 2020[30]. - The overall gross margin for the company was 91.07%, an increase of 0.53 percentage points compared to the previous year[158]. - The company reported a total revenue of 13,086 million RMB, with a net profit of 5,890.03 million RMB, indicating a strong financial performance[126]. Dividend and Capital Structure - The company plans to distribute a cash dividend of 5.00 CNY per 10 shares, totaling 48,219,154.00 CNY, which represents 94.18% of the net profit attributable to the parent company[7]. - The company intends to increase its total share capital by 38,575,323 shares through a capital reserve conversion, raising the total share capital to 135,013,631 shares[7]. Research and Development - The company is investing RMB 100 million in R&D for new technologies in minimally invasive surgical procedures[22]. - R&D expenditure accounted for 23.39% of operating revenue, up 7.58 percentage points from 15.81% in 2020[30]. - R&D investment increased by 104.73% year-on-year, primarily due to significant clinical trial expenses for three interventional valve products, with total R&D expenses amounting to ¥58,900,391.29[116]. - The company has established a strong R&D team with over 10 ongoing projects, including interventional valves and biological patches for ophthalmology and vascular applications[138]. - The company has developed a unique core technology and independent intellectual property rights in animal tissue modification, enabling the industrialization of various biological valve and patch products[132]. Market Expansion and Product Development - The company has set a revenue guidance of RMB 1.5 billion for the fiscal year 2022, projecting a growth rate of 25%[22]. - Market expansion efforts have led to a 40% increase in sales in the Asia-Pacific region[22]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[22]. - The company is focusing on expanding its product line with innovative solutions, including a new expandable aortic valve system, to address patient needs and market gaps[122]. - The company is developing a cardiac arrhythmia treatment system to address the needs of rheumatic valve disease patients who often have atrial fibrillation, currently undergoing ethical approval[100]. Clinical Trials and Product Innovation - The company conducted extensive clinical trials for its interventional valve products, contributing to the overall revenue growth despite ongoing pandemic challenges[32]. - The company successfully completed the first trial of the RenatoTM transcatheter valve-in-valve system on March 5, 2021, with a 100% success rate in a clinical trial involving 150 high-risk patients[92]. - The company is actively involved in clinical trials for new products, including a new type of tricuspid/mitral valve ring and an interventional pulmonary valve system[62]. - The company has focused on personalized product design and technological updates for existing products, providing strong evidence for the design and confirmation of new valve products[88]. Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm[6]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance[6]. - The company has not disclosed any special arrangements for corporate governance[9]. - The company has strengthened its governance structure and internal control systems, ensuring compliance with relevant laws and regulations, with no issues requiring rectification by regulatory authorities as of the end of the reporting period[186]. - The independent directors have not raised any objections to the resolutions made during board meetings, indicating a unified approach to governance[189]. Risks and Challenges - The company has outlined potential risk factors in its operations, which can be found in the management discussion and analysis section[5]. - The company faces risks related to the declining competitiveness of existing products due to the expansion of interventional valve applications[143]. - There is a risk of market development challenges for innovative products, influenced by entrenched clinical practices and lengthy procurement processes[144]. - The company is subject to strict regulatory oversight in the animal-derived implantable medical device industry, which could impact product sales if compliance is not met[145]. Marketing and Sales Strategy - The company has strengthened its marketing capabilities and brand promotion to enhance market competitiveness and influence[51]. - The sales strategy is primarily focused on domestic markets, utilizing a network of distributors and direct sales to hospitals, with no current international sales[70]. - The company expanded its marketing team and focused on key hospital development to enhance market penetration[158]. Talent and Management - The company continues to recruit talent and improve management efficiency to support business expansion and operational effectiveness[53]. - The company has increased its R&D personnel to 45, representing 15.85% of the total workforce, with an average salary of 18.23 million RMB, reflecting a commitment to innovation[128]. - The total pre-tax remuneration for the chairman and general manager, Jin Lei, was 740,000 yuan for the reporting period[198].

Financial Performance - The company's operating revenue for Q1 2022 was ¥66,005,581.98, representing a year-on-year increase of 26.34%[7] - Net profit attributable to shareholders was ¥13,606,919.59, reflecting a growth of 53.54% compared to the same period last year[7] - Basic earnings per share (EPS) was ¥0.14, up by 55.56% year-on-year[7] - Net profit for Q1 2022 reached CNY 13,570,614.66, compared to CNY 8,611,688.66 in Q1 2021, representing a significant increase of 57.5%[38] - The total comprehensive income for the period attributable to the parent company was CNY 13,780,828.74, compared to CNY 8,861,895.35 in the same period last year, representing a significant increase[41] Cash Flow - The net cash flow from operating activities reached ¥23,085,270.23, marking a significant increase of 73.21%[7] - Cash inflows from operating activities totaled CNY 71,507,150.55, compared to CNY 55,580,050.73 in the previous year, reflecting a growth of approximately 28.6%[45] - Net cash generated from operating activities was CNY 23,085,270.23, an increase from CNY 13,327,777.39 in the prior year, showing a year-over-year growth of about 73.5%[45] - The net increase in cash and cash equivalents for the period was CNY 32,896,749.65, compared to CNY 24,680,037.48 in the same period last year, indicating a growth of approximately 33.3%[47] - The ending balance of cash and cash equivalents was CNY 185,040,249.87, up from CNY 174,252,997.00 year-over-year[47] Research and Development - Total R&D investment amounted to ¥14,695,524.66, which is an increase of 43.25% from the previous year[9] - The proportion of R&D investment to operating revenue was 22.26%, an increase of 2.62 percentage points[9] - Research and development expenses for Q1 2022 were CNY 14,695,524.66, an increase of 43.0% compared to CNY 10,258,979.46 in Q1 2021[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,054,828,220.41, a 2.32% increase from the end of the previous year[9] - The company's total liabilities included accounts payable of ¥21.99 million, which increased from ¥15.30 million, indicating a growth of approximately 43.5%[30] - The company's total liabilities increased to CNY 47,665,564.92 from CNY 42,728,523.60, indicating a rise of 7.0%[35] - The total equity attributable to shareholders of the parent company rose to CNY 1,008,512,481.43 from CNY 989,510,316.64, reflecting a growth of 1.0%[35] Shareholder Information - The company reported a total of 2,000,853 shares held by China Industrial Bank Co., Ltd. - China Europe Value Smart Selection Mixed Securities Investment Fund, making it the largest shareholder[22] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest holding being 2,000,853 shares[22] - The company has a total of 561,070 shares held by Guoxin Securities - Bank of China - Guoxin Securities Dingxin No. 2 Science and Technology Innovation Board Strategic Placement Collective Asset Management Plan[22] Operating Costs and Revenue Segments - Total operating costs for Q1 2022 were CNY 52,611,993.70, up from CNY 46,798,690.45 in Q1 2021, reflecting a growth of 12.0%[35] - Revenue from the heart valve replacement and repair segment grew by 28.29%, with artificial biological heart valve sales increasing by 44.91%[10]